ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-nectin-4 Antibody-drug Conjugate MK-3120

Also written as “MK-3120” and “SKB410 for injection”.

Its studies are mostly in Urinary Bladder Neoplasms · Neoplasms · Carcinoma, Transitional Cell, led by 2 companies.

Drug pageAnti-nectin-4 Antibody-drug Conjugate MK-3120: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 28, 20225 company-led studies, 4 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only44 open or runningphase 2since Sep 28, 2022Sep 28, 2022Jul 30, 2027phase 2 · NCT07222488
Sichuan Kelun Pharmaceuticalits history only10 open or runningphase 1since May 16, 2023May 16, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2022First study: phase 2 study in Carcinoma, Transitional CellNew to MerckMerck · NCT05562830 · 48 enrolled · United States, Australia, Canada and more
  2. May 16, 2023Sichuan Kelun Pharmaceutical’s first study: phase 1 study in Advanced Solid TumorsNew to Sichuan Kelun PharmaceuticalSichuan Kelun Pharmaceutical · NCT05906537 · 38 enrolled · China
  3. Feb 7, 2025Phase 2 study in NeoplasmsMerck · NCT06818643 · 270 planned · United States, Chile, China and more
  4. Oct 27, 2025Phase 2 study in Urinary Bladder NeoplasmsMerck · NCT07222488 · 45 planned · United States, Austria, Belgium and more
  5. Nov 14, 2025Phase 2 study in Urinary Bladder NeoplasmsMerck · NCT07232602 · 55 planned · United States, Chile, France and more
  6. Oct 6, 2026Primary completion moved from 2028-10-25 to 2031-03-07Date moved laterphase 2 · +28 months · NCT06818643

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT07222488
  2. Feb 8, 2028Primary completion: phase 2 study in NeoplasmsMerck · NCT06818643
  3. Feb 26, 2029Primary completion: phase 2 study in Carcinoma, Transitional CellMerck · NCT05562830
  4. Jul 8, 2031Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT07232602

TargetBeta

NECTIN4 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4) ”NCIt, by rule

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
enfortumab vedotinruleAstellas Pharmaphase 420
notiretatug rezetecanJiangsu HengRui Medicinephase 314
bulumtatug fuvedotinruleMabwell (Shanghai) Biosciencephase 313
Sutantatug EnvedotinruleCSPC Pharmaceutical Groupphase 36
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleinnate-pharmaphase 11
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11
CT-202rulecontext-therapeutics-incphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07232602Urinary Bladder Neoplasms · United States, Chile, France and more2RecruitingMerckJul 8, 203155
NCT07222488Urinary Bladder Neoplasms · United States, Austria, Belgium and more2RecruitingMerckJul 30, 202745
NCT06818643Neoplasms · United States, Chile, China and more2RecruitingMerckFeb 8, 2028270
NCT05906537Advanced Solid Tumors · China1CompletedSichuan Kelun PharmaceuticalMar 31, 202638
NCT05562830Carcinoma, Transitional Cell · United States, Australia, Canada and more2Active, not recruitingMerckFeb 26, 202948

How it is read

Names in the registry

  • “MK-3120”, 4 entries
  • “SKB410 for injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.